Coudert, Bruno <br/><br/>
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.  [electronic resource] 

 -  The oncologist  2012 
 - 900-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1549-490X 
<br/><br/><label>Standard No.: </label>10.1634/theoncologist.2011-0442  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Combined Modality Therapy<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Docetaxel<br/>Drug Administration Schedule<br/>Epirubicin--administration & dosage<br/>Female<br/>Fluorouracil--administration & dosage<br/>Follow-Up Studies<br/>Humans<br/>Lymphatic Metastasis<br/>Middle Aged<br/>Survival Rate<br/>Taxoids--administration & dosage<br/>Young Adult